As in many cases with diabetes technology, there is often a large gray area nestled between FDA indication and patient application. Take continuous glucose monitoring for example. With minimal calibrations and impressive leaps in accuracy, many patients use current generations of CGM devices for insulin dosing decisions despite a lack of an FDA indication to do so.
But this is one gray area that’s about to get a little clearer. According to a recent Diabetes Mine article, a new study is underway that will evaluate the safety and effectiveness of CGM based dosing compared to CGM plus fingerstick. If results from the "Replace-BG Study" confirm what many folks suspect, it would be a landmark clinical trial at a critical time for both artificial pancreas developments and insurance coverage deliberations.
What are your thoughts on CGM-based dosing decisions? Do you think we are “there” yet?
To learn more about this and other diabetes research studies, visit www.clinicaltrials.gov.